Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Forbes

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Diabetologia|February 24, 2001
Renoprotective effects of a novel inhibitor of advanced glycationJ M Forbes, T Soulis, V Thallas, et al.
Diabetologia|December 3, 2003
Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive ratB J Davis, J M Forbes, M C Thomas, et al.
Diabetes/Metabolism Research and Reviews|November 25, 2016
A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetesK M Salonen, S J Ryhänen, J M Forbes, et al.
Kidney International|December 15, 2000
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosisZ Cao, D J Kelly, A Cox, et al.
Diabetologia|March 1, 2012
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetesK Huynh, H Kiriazis, X-J Du, et al.
Current Eye Research|March 15, 2005
Identification of angiotensin converting enzyme 2 in the rodent retinaC Tikellis, C I Johnston, J M Forbes, et al.
Diabetologia|June 21, 2007
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic propertiesA Hoang, A J Murphy, M T Coughlan, et al.
The Journal of Clinical Investigation|December 19, 2001
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)M D Oldfield, L A Bach, J M Forbes, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 21, 2010
Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycansR Mangat, J W Su, J E Lambert, et al.
Diabetologia|July 16, 2010
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptorK C Sourris, A L Morley, A Koitka, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Diabetologia|February 24, 2001
Renoprotective effects of a novel inhibitor of advanced glycationJ M Forbes, T Soulis, V Thallas, et al.
Diabetologia|December 3, 2003
Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive ratB J Davis, J M Forbes, M C Thomas, et al.
Diabetes/Metabolism Research and Reviews|November 25, 2016
A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetesK M Salonen, S J Ryhänen, J M Forbes, et al.
Kidney International|December 15, 2000
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosisZ Cao, D J Kelly, A Cox, et al.
Diabetologia|March 1, 2012
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetesK Huynh, H Kiriazis, X-J Du, et al.
Current Eye Research|March 15, 2005
Identification of angiotensin converting enzyme 2 in the rodent retinaC Tikellis, C I Johnston, J M Forbes, et al.
Diabetologia|June 21, 2007
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic propertiesA Hoang, A J Murphy, M T Coughlan, et al.
The Journal of Clinical Investigation|December 19, 2001
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)M D Oldfield, L A Bach, J M Forbes, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 21, 2010
Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycansR Mangat, J W Su, J E Lambert, et al.
Diabetologia|July 16, 2010
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptorK C Sourris, A L Morley, A Koitka, et al.
Pageof 14